A new look at dry eye disease and its treatment

This review examines the impact of moderate to severe dry eye disease on da ily life and medical-resource utilization. The results suggest that current treatment paradigms can lead to unacceptable costs in both quality of life and progressive use of healthcare resources. Evidence linking this disease to T-cell-mediated inflammatory processes lays the foundation for understa nding the clinical benefits of topical cyclosporine, an immunomodulatory an d anti-inflammatory agent.